化疗诱导的中性粒细胞减少症及预防和治疗的新型药物：综述 - Suppr

Suppr

超能文献

Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review.

作者信息

Blayney Douglas W, Schwartzberg Lee

机构信息

Stanford Cancer Institute, Stanford, CA, United States.

Renown Institute for Cancer, University of Nevada, Reno, Reno, NV, United States.

出版信息

Cancer Treat Rev. 2022 Sep;109:102427. doi: 10.1016/j.ctrv.2022.102427. Epub 2022 Jun 21.

DOI:10.1016/j.ctrv.2022.102427

PMID:35785754

Abstract

摘要

相似文献

Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review.

Cancer Treat Rev. 2022 Sep;109:102427. doi: 10.1016/j.ctrv.2022.102427. Epub 2022 Jun 21.

Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.

Oncologist. 2020 Aug;25(8):e1233-e1241. doi: 10.1634/theoncologist.2020-0105. Epub 2020 Jun 16.

Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.

J Clin Pharmacol. 2021 Feb;61(2):204-210. doi: 10.1002/jcph.1723. Epub 2020 Aug 21.

[Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors].

Farm Hosp. 2010 Mar;34 Suppl 1:8-11. doi: 10.1016/S1130-6343(10)70002-7.

Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.

Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD007913. doi: 10.1002/14651858.CD007913.pub2.

Agents under investigation for the treatment and prevention of neutropenia.

Expert Opin Investig Drugs. 2007 Nov;16(11):1831-40. doi: 10.1517/13543784.16.11.1831.

Colony-stimulating factors for the management of neutropenia in cancer patients.

Drugs. 2002;62 Suppl 1:1-15. doi: 10.2165/00003495-200262001-00001.

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.

Cancer Med. 2020 Sep;9(17):6234-6243. doi: 10.1002/cam4.3227. Epub 2020 Jul 20.

Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.

Pharmacoeconomics. 2003;21(18):1295-313. doi: 10.1007/BF03262329.

Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer.

Am J Clin Oncol. 2000 Jun;23(3):278-82. doi: 10.1097/00000421-200006000-00014.

引用本文的文献

Synergistic effect of regorafenib with aminoglycosides in ferroptosis-mediated liver injury.

Front Pharmacol. 2025 Jul 15;16:1586578. doi: 10.3389/fphar.2025.1586578. eCollection 2025.

Cobalt protoporphyrin IX induces transient, dose- and time-dependent granulocyte mobilization with mild metabolic effects in mice.

Pharmacol Rep. 2025 Jul 9. doi: 10.1007/s43440-025-00751-4.

Anesthetic considerations for outpatient interventional radiology procedures for cancer patients.

Curr Opin Anaesthesiol. 2025 Aug 1;38(4):383-390. doi: 10.1097/ACO.0000000000001515. Epub 2025 May 20.

Microbiome-Induced Microenvironmental Changes Before and After Breast Cancer Treatment.

Microorganisms. 2025 May 1;13(5):1057. doi: 10.3390/microorganisms13051057.

Microneedle Patch for In Situ Neutrophil Monitoring.

Adv Sci (Weinh). 2025 Jun;12(23):e2417801. doi: 10.1002/advs.202417801. Epub 2025 May 8.

8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial.

Breast Cancer Res. 2025 May 6;27(1):71. doi: 10.1186/s13058-025-02010-z.

Mecapegfilgrastim prophylaxis for neutropenia in patients with non-myeloid malignancies: A Chinese nationwide real-world study.

BMC Cancer. 2025 Apr 21;25(1):742. doi: 10.1186/s12885-025-14144-6.

Secondary Neutropenias.

Biomedicines. 2025 Feb 17;13(2):497. doi: 10.3390/biomedicines13020497.

Colonization of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci and its associated factors in cancer patients at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.

PLoS One. 2025 Feb 7;20(2):e0318242. doi: 10.1371/journal.pone.0318242. eCollection 2025.

How Can Oncology Nurses and Advanced Practice Providers Reduce the Burden of Chemotherapy-Induced Febrile Neutropenia in the US?

J Adv Pract Oncol. 2024 May 22:1-15. doi: 10.6004/jadpro.2024.15.8.5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review.

作者信息

Blayney Douglas W, Schwartzberg Lee

机构信息

Stanford Cancer Institute, Stanford, CA, United States.

Renown Institute for Cancer, University of Nevada, Reno, Reno, NV, United States.

出版信息

Cancer Treat Rev. 2022 Sep;109:102427. doi: 10.1016/j.ctrv.2022.102427. Epub 2022 Jun 21.

DOI:10.1016/j.ctrv.2022.102427

PMID:35785754

Abstract

摘要

相似文献

Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review.

Cancer Treat Rev. 2022 Sep;109:102427. doi: 10.1016/j.ctrv.2022.102427. Epub 2022 Jun 21.

Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.

Oncologist. 2020 Aug;25(8):e1233-e1241. doi: 10.1634/theoncologist.2020-0105. Epub 2020 Jun 16.

Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.

J Clin Pharmacol. 2021 Feb;61(2):204-210. doi: 10.1002/jcph.1723. Epub 2020 Aug 21.

[Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors].

Farm Hosp. 2010 Mar;34 Suppl 1:8-11. doi: 10.1016/S1130-6343(10)70002-7.

Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.

Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD007913. doi: 10.1002/14651858.CD007913.pub2.

Agents under investigation for the treatment and prevention of neutropenia.

Expert Opin Investig Drugs. 2007 Nov;16(11):1831-40. doi: 10.1517/13543784.16.11.1831.

Colony-stimulating factors for the management of neutropenia in cancer patients.

Drugs. 2002;62 Suppl 1:1-15. doi: 10.2165/00003495-200262001-00001.

Cancer Med. 2020 Sep;9(17):6234-6243. doi: 10.1002/cam4.3227. Epub 2020 Jul 20.

Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.

Pharmacoeconomics. 2003;21(18):1295-313. doi: 10.1007/BF03262329.

Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer.

Am J Clin Oncol. 2000 Jun;23(3):278-82. doi: 10.1097/00000421-200006000-00014.

引用本文的文献

Synergistic effect of regorafenib with aminoglycosides in ferroptosis-mediated liver injury.

Front Pharmacol. 2025 Jul 15;16:1586578. doi: 10.3389/fphar.2025.1586578. eCollection 2025.

Cobalt protoporphyrin IX induces transient, dose- and time-dependent granulocyte mobilization with mild metabolic effects in mice.

Pharmacol Rep. 2025 Jul 9. doi: 10.1007/s43440-025-00751-4.

Anesthetic considerations for outpatient interventional radiology procedures for cancer patients.

Curr Opin Anaesthesiol. 2025 Aug 1;38(4):383-390. doi: 10.1097/ACO.0000000000001515. Epub 2025 May 20.

Microbiome-Induced Microenvironmental Changes Before and After Breast Cancer Treatment.

Microorganisms. 2025 May 1;13(5):1057. doi: 10.3390/microorganisms13051057.

Microneedle Patch for In Situ Neutrophil Monitoring.

Adv Sci (Weinh). 2025 Jun;12(23):e2417801. doi: 10.1002/advs.202417801. Epub 2025 May 8.

8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial.

Breast Cancer Res. 2025 May 6;27(1):71. doi: 10.1186/s13058-025-02010-z.

Mecapegfilgrastim prophylaxis for neutropenia in patients with non-myeloid malignancies: A Chinese nationwide real-world study.

BMC Cancer. 2025 Apr 21;25(1):742. doi: 10.1186/s12885-025-14144-6.

Secondary Neutropenias.

Biomedicines. 2025 Feb 17;13(2):497. doi: 10.3390/biomedicines13020497.

PLoS One. 2025 Feb 7;20(2):e0318242. doi: 10.1371/journal.pone.0318242. eCollection 2025.

How Can Oncology Nurses and Advanced Practice Providers Reduce the Burden of Chemotherapy-Induced Febrile Neutropenia in the US?

J Adv Pract Oncol. 2024 May 22:1-15. doi: 10.6004/jadpro.2024.15.8.5.